BALPHARMA vs HIKAL: Stock Comparison
HIKAL is the larger company by market capitalisation. BAL PHARMA shows a higher ROE, a higher dividend yield and a higher ROCE, while HIKAL shows faster revenue growth and lower leverage. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
BALPHARMA leads 7; HIKAL leads 4 of 11
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | BALPHARMA | HIKAL |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | BALPHARMA | HIKAL |
|---|---|---|
| Live Price | ₹87.73 | ₹222.3 |
| Day Change | 0.02% | -7.51% |
| Volume | 8,210 | 53.59 L |
| 52-Week High | ₹98.85 | ₹282.7 |
| 52-Week Low | ₹60 | ₹146.25 |
| Distance from 52W High | -11.25% | -21.37% |
Valuation
| Metric | BALPHARMA | HIKAL |
|---|---|---|
| Market Cap | ₹141 Cr | ₹2,740 Cr |
| P/E Ratio | — | 0x |
| P/B Ratio | — | 2.07x |
| EPS | ₹0.71 | ₹-0.6 |
| Book Value | ₹51.66 | ₹97.23 |
| Dividend Yield | 1.36% | 0.09% |
Growth
| Metric | BALPHARMA | HIKAL |
|---|---|---|
| Revenue Growth (TTM YoY) | 2.7% | 37.3% |
| EPS Growth (TTM YoY) | -33.5% | 68.3% |
| Qtr Sales Growth | 0.21% | 0% |
| Qtr Profit Growth | -2.01% | 1.33% |
Profitability & Leverage
| Metric | BALPHARMA | HIKAL |
|---|---|---|
| ROE | 7.69% | -4.07% |
| ROCE | 9.5% | -0.87% |
| Net Margin | 2.02% | -2.88% |
| Operating Margin | 7.3% | -0.95% |
| Debt to Equity | 1.94x | 0.57x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | BALPHARMA | HIKAL |
|---|---|---|
| Promoter Holding | 46.74% | 68.85% |
| FII Holding | 0.15%▲ 0.01 pp | 0.99%▼ 0.44 pp |
| DII Holding | 0% | 7.24%▲ 0.04 pp |
| Public Holding | 48.99%▼ 0.02 pp | 22.93%▲ 0.41 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: BAL PHARMA and HIKAL.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.